BridgeMD
New treatment option for PARKINSON DISEASE (Disorder)
Official title Whole-Body Photobiomodulation for Motor and Cognitive Changes in Parkinson's Disease
ClinicalTrials.gov ID: NCT07271927
What this study is testing
- What it's testing
- This study aims to exploratorily evaluate the extent of motor and cognitive changes, as well as the safety, resulting from approximately 10 weeks of whole-body photobiomodulation (PBM) therapy (about three sessions per week, once daily, 20 minutes per session) in patients with Parkinson's disease.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 40 and older
You may be able to join if
- Individuals diagnosed with Parkinson's disease at Hoehn and Yahr stages 1-3 based on medical history and examination
- Adults aged 40 years or older
- Individuals able to walk independently
You likely can't join if
- Individuals with severe cognitive impairment (Korean Mini-Mental State Examination [K-MMSE] score ≤ 9) making it difficult to understand and perform...
- Patients with dementia other than Parkinson's disease dementia
- Individuals with implanted medical or other electronic devices
- Individuals with severe neuropsychiatric disorders
- Individuals treated for alcohol dependence within 6 months prior to screening
- Individuals with a history of suicide attempts
See the full eligibility criteria
- Individuals diagnosed with Parkinson's disease at Hoehn and Yahr stages 1-3 based on medical history and examination
- Adults aged 40 years or older
- Individuals able to walk independently
- Individuals with severe cognitive impairment (Korean Mini-Mental State Examination [K-MMSE] score ≤ 9) making it difficult to understand and perform tasks
- Patients with dementia other than Parkinson's disease dementia
- Individuals with implanted medical or other electronic devices
- Individuals with severe neuropsychiatric disorders
- Individuals treated for alcohol dependence within 6 months prior to screening
- Individuals with a history of suicide attempts
- Individuals with a history of seizures
- Individuals experiencing dyspnea while sitting at rest
- Individuals with visual impairment preventing them from reading ordinary text even with corrective lenses
- Individuals with hearing impairment preventing them from understanding conversation even with a hearing aid
- Individuals who have participated in two or more clinical trials in the same year or in another clinical trial within the past 6 months
- Women and men of childbearing potential who are planning pregnancy during the trial or who do not agree to use appropriate contraceptive methods
- Pregnant or breastfeeding women
- Individuals deemed medically inappropriate for participation by the principal investigator or study staff based on clinically significant findings not otherwise specified above
The study team makes the final eligibility decision.
Where it's taking place
- Yangsan, Gyeongsangnam-do, South Korea
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 40 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Yangsan, Gyeongsangnam-do, South Korea. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.